WO2006129158B1 - 3 - indazolyl - isoxazoline derivatives as inhibitors of phosphodiesterase type - i - Google Patents

3 - indazolyl - isoxazoline derivatives as inhibitors of phosphodiesterase type - i

Info

Publication number
WO2006129158B1
WO2006129158B1 PCT/IB2006/001383 IB2006001383W WO2006129158B1 WO 2006129158 B1 WO2006129158 B1 WO 2006129158B1 IB 2006001383 W IB2006001383 W IB 2006001383W WO 2006129158 B1 WO2006129158 B1 WO 2006129158B1
Authority
WO
WIPO (PCT)
Prior art keywords
formula
inhibitors
phosphodiesterase
type
pde
Prior art date
Application number
PCT/IB2006/001383
Other languages
French (fr)
Other versions
WO2006129158A2 (en
WO2006129158A3 (en
Inventor
Venkata P Palle
Sarala Balachandran
Lalit Kumar Baregama
Saswati Chakladar
Sarika Ramnani
Nagarajan Muthukamal
Abhijit Ray
Sunanda G Dastidar
Original Assignee
Ranbaxy Lab Ltd
Venkata P Palle
Sarala Balachandran
Lalit Kumar Baregama
Saswati Chakladar
Sarika Ramnani
Nagarajan Muthukamal
Abhijit Ray
Sunanda G Dastidar
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Lab Ltd, Venkata P Palle, Sarala Balachandran, Lalit Kumar Baregama, Saswati Chakladar, Sarika Ramnani, Nagarajan Muthukamal, Abhijit Ray, Sunanda G Dastidar filed Critical Ranbaxy Lab Ltd
Priority to EP06744776A priority Critical patent/EP1891060A2/en
Publication of WO2006129158A2 publication Critical patent/WO2006129158A2/en
Publication of WO2006129158A3 publication Critical patent/WO2006129158A3/en
Publication of WO2006129158B1 publication Critical patent/WO2006129158B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to isoxazoline derivatives, of formula (I a) which can be used as selective inhibitors of phosphodiesterase (PDE) type IV. Compounds disclosed herein can be useful in treating AIDS, asthma, arthritis, bronchitis, chronic obstructive pulmonary disease (COPD), psoriasis, allergic rhinitis, shock, atopic dermatitis, Crohn's disease, adult respiratory distress syndrome (ARDS), eosinophilic granuloma, allergic conjunctivitis, osteoarthritis, ulcerative colitis or other inflammatory diseases especially in humans. Processes for preparing compounds described herein are provided, as well as pharmaceutical compositions comprising compounds described herein, and their use as phosphodiesterase (PDE) type IV inhibitors.

Claims

AMENDED CLAIMS received by the International Bureau on February 2, 2007
Figure imgf000002_0001
Formula III c. reacting the compound of Formula III with a compound of Formula IV
Figure imgf000002_0002
Formula IV to form a compound of Formula V,
Figure imgf000002_0003
Formula V d. reducing the compound of Formula V to form a compound of Formula VI,
Figure imgf000002_0004
Formula Vl e. cyclizing a compound of Formula VI to form a compound of Formula VII,
Figure imgf000002_0005
Formula VlI
wherein
hal is Br, Cl or I;
39
PCT/IB2006/001383 2005-05-30 2006-05-26 3 - indazolyl - isoxazoline derivatives as inhibitors of phosphodiesterase type - i WO2006129158A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP06744776A EP1891060A2 (en) 2005-05-30 2006-05-26 3-indazolyl-isoxazoline derivatives as inhibitors of phosphodiesterase type-iv

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1381DE2005 2005-05-30
IN1381/DEL/2005 2005-05-30

Publications (3)

Publication Number Publication Date
WO2006129158A2 WO2006129158A2 (en) 2006-12-07
WO2006129158A3 WO2006129158A3 (en) 2007-11-22
WO2006129158B1 true WO2006129158B1 (en) 2007-12-27

Family

ID=37307042

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2006/001383 WO2006129158A2 (en) 2005-05-30 2006-05-26 3 - indazolyl - isoxazoline derivatives as inhibitors of phosphodiesterase type - i

Country Status (2)

Country Link
EP (1) EP1891060A2 (en)
WO (1) WO2006129158A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1928866A1 (en) 2005-09-05 2008-06-11 Ranbaxy Laboratories Limited Substituted indazoles as inhibitors of phosphodiesterase type-iv
WO2009022746A1 (en) * 2007-08-10 2009-02-19 Nippon Soda Co., Ltd. Nitrogen-containing heterocyclic compound and pest control agent
CA2799154A1 (en) 2010-05-12 2011-11-17 Abbvie Inc. Indazole inhibitors of kinase

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0912558T3 (en) * 1996-06-25 2003-08-18 Pfizer Substituted Indazole Derivatives and Their Use as Phosphodiesterase (PDE) Type IV Inhibitors and Tumor Necrosis Factor (TNF)
TR199900481T2 (en) * 1996-09-04 1999-06-21 Pfizer Inc. Indazole derivatives; their use as phosphodiesterase type IV inhibitors.
WO2001047915A1 (en) * 1999-12-23 2001-07-05 Icos Corporation Cyclic amp-specific phosphodiesterase inhibitors

Also Published As

Publication number Publication date
EP1891060A2 (en) 2008-02-27
WO2006129158A2 (en) 2006-12-07
WO2006129158A3 (en) 2007-11-22

Similar Documents

Publication Publication Date Title
WO2005021515A3 (en) Inhibitors of phosphodiesterase type-iv
WO2006085212A3 (en) Condensed isoxaline derivatives as inhibitors of phosphodiesterase type-iv
WO2008035315A3 (en) Inhibitors of phosphodiesterase type-iv
JP2016034968A5 (en)
EA200970852A1 (en) PYRAZOLO [3,4-B] PYRIDINE DERIVATIVES AS PHOSPHODESTERASE INHIBITORS
SG166121A1 (en) Pyrimidine amide compounds as pgds inhibitors
EP1270577A4 (en) Furoisoquinoline derivatives, process for producing the same and use thereof
TNSN08339A1 (en) 2,6 -substituted-4-monosubstituted amino-pyrimidine as prostaglandin d2 receptor antagonists
WO2009074575A3 (en) Organic compounds
JP2011510970A5 (en)
TNSN07251A1 (en) 2-phenyl-indoles as prostaglandin d2 receptor antagonists
JP2008510762A5 (en)
WO2008094992A3 (en) 2-aminopyridine derivatives useful as kinase inhibitors
JP2009536918A5 (en)
WO2006015860A3 (en) Pyrazole derivatives for treating conditions mediated by activation of the adenosine a2b or a3 receptor
BRPI0517211B8 (en) compound, pharmaceutical composition and its use.
WO2008055814A3 (en) Process for the preparation of (s)-4-fluoromethyl-dihydro-furan-2-one
TW200637863A (en) Organic compounds
WO2006002434A3 (en) Novel indazole carboxamides and their use
JP2016540749A5 (en)
MXPA04007736A (en) Nicotinamide derivatives useful as pde4 inhibitors.
MX2009008509A (en) Aza-bridged-ring compound.
WO2007031829A3 (en) Novel pyrimidine carboxamides
WO2005051931A3 (en) Phosphodiesterase inhibitors
JP2009504676A5 (en)

Legal Events

Date Code Title Description
NENP Non-entry into the national phase in:

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 9365/DELNP/2007

Country of ref document: IN

Ref document number: 2006744776

Country of ref document: EP

NENP Non-entry into the national phase in:

Ref country code: RU

WWW Wipo information: withdrawn in national office

Ref document number: RU

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06744776

Country of ref document: EP

Kind code of ref document: A2

WWP Wipo information: published in national office

Ref document number: 2006744776

Country of ref document: EP